Skip to main content
Top
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Mastectomy | Research article

Comparison between opportunistic and organised breast cancer mammography screening in the Swiss canton of Fribourg

Authors: Sarah Peisl, Stefan Zimmermann, Bertrand Camey, Daniel Betticher, Christine Bouchardy

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

Breast cancer screening mammography is widespread in industrialised countries within the framework of public health program or opportunist form. Only few data exist on the comparison of effectiveness between organised and opportunistic screening. The aim of this study is to compare organised and opportunistic screening using population-based data from the Fribourg cancer registry, Switzerland.

Methods

We included all first primary breast adenocarcinoma diagnosed between 2006 and 2014 in women aged 50–69 years resident in the canton of Fribourg. We considered only breast cancer discovered by mammography screening. We compared patients, tumour characteristics and treatment modalities between breast cancer detected by the organised screening program versus opportunistic screening using logistic regression.

Results

Out of 989 patients diagnosed with breast cancer, 402 (40.6%) were diagnosed by organised and 205 (20.7%) by opportunistic screening. Women with breast cancer detected within the screening program were more likely to be from rural areas (P = 0.035) and lived less frequently in high favoured regions (P = 0.020). They presented more frequently in situ than invasive cancer (P = 0.022). For patients with invasive breast cancer, those detected by the program were less likely to undergo mastectomy (P = 0.06) and consequently, they were more likely to undergo radiation therapy (P = 0.003). Adjustment for area of residence and financial context of the region did not modify the results presented.

Conclusions

The present study reports an increased rate of detection of carcinoma in situ in organised screening program as compared to opportunistic screening mammographies, an indirect evidence of a higher radiologic sensitivity. Furthermore, the results show a trend towards more mastectomies among patients with breast cancer discovered after opportunistic than after organized mammography screening, reflecting lower treatment burden. Those results were independent of socio-economic factors which differed across screening groups.
Literature
1.
go back to reference Stewart BW, Wild CP. World cancer report, International agency for research on cancer. ISBN 978-92-832-0443-5, 2014. Stewart BW, Wild CP. World cancer report, International agency for research on cancer. ISBN 978-92-832-0443-5, 2014.
2.
go back to reference Bundesamt für Statistik. Schweizerischer Krebsbericht. ISBN 978–3–303-14235-6, 2015. Bundesamt für Statistik. Schweizerischer Krebsbericht. ISBN 978–3–303-14235-6, 2015.
3.
go back to reference Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast Cancer. N Engl J Med. 2005;353:1784–92.CrossRef Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast Cancer. N Engl J Med. 2005;353:1784–92.CrossRef
4.
go back to reference Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2011;(1):CD001877. Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2011;(1):CD001877.
5.
go back to reference Njor S, Nyström L, Moss S, et al. Breast cancer mortality in mammographic screening in Europe: a review of incidence-based mortality studies. J Med Screen. 2012;19(Suppl 1):33–41.CrossRef Njor S, Nyström L, Moss S, et al. Breast cancer mortality in mammographic screening in Europe: a review of incidence-based mortality studies. J Med Screen. 2012;19(Suppl 1):33–41.CrossRef
6.
go back to reference Perry N, Broeders M, De Wolf C, et al. European guidelines for quality assurance in breast Cancer screening and diagnosis, 4th Edition. European Commission, 2006. Perry N, Broeders M, De Wolf C, et al. European guidelines for quality assurance in breast Cancer screening and diagnosis, 4th Edition. European Commission, 2006.
7.
8.
go back to reference Bulliard JL, Zwahlen M, Fracheboud J. Monitoring Report 2012. Report, Swiss cancer screening, December 2015. Bulliard JL, Zwahlen M, Fracheboud J. Monitoring Report 2012. Report, Swiss cancer screening, December 2015.
9.
go back to reference Krebsliga Freiburg. Jahresbericht 2006 – 2014. In: Report; 2015. Krebsliga Freiburg. Jahresbericht 2006 – 2014. In: Report; 2015.
10.
go back to reference Camey B. Le cancer du sein dans le canton de Fribourg, analyses statistiques réalisées sur la base des données récoltées par le Registre fribourgeois des tumeurs depuis début 2006. Report, Cancer registry of Fribourg, Switzerland, September 2012. Camey B. Le cancer du sein dans le canton de Fribourg, analyses statistiques réalisées sur la base des données récoltées par le Registre fribourgeois des tumeurs depuis début 2006. Report, Cancer registry of Fribourg, Switzerland, September 2012.
11.
go back to reference Bulliard JL, Ducros C, Jemelin C, Arzel B, Fioretta G, Levi F. Effectiveness of organised versus opportunistic mammography screening. Ann Oncol. 2009;20:1199–202.CrossRef Bulliard JL, Ducros C, Jemelin C, Arzel B, Fioretta G, Levi F. Effectiveness of organised versus opportunistic mammography screening. Ann Oncol. 2009;20:1199–202.CrossRef
12.
go back to reference Hofvind S, Vacek PM, Skelly J, Weaver DL, Geller BM. Comparing screening mammography for early breast cancer detection in Vermont and Norway. J Natl Cancer Inst. 2008;100:1082–91.CrossRef Hofvind S, Vacek PM, Skelly J, Weaver DL, Geller BM. Comparing screening mammography for early breast cancer detection in Vermont and Norway. J Natl Cancer Inst. 2008;100:1082–91.CrossRef
13.
go back to reference Vanier A, Leux C, Allioux C, Billon-Delacour S, Lombrail P, Molinié F. Are prognostic factors more favorable for breast cancer detected by organized screening than by opportunistic screening or clinical diagnosis? A study in Loire-Atlantique (France). Cancer Epidemiol. 2013;37:683–7.CrossRef Vanier A, Leux C, Allioux C, Billon-Delacour S, Lombrail P, Molinié F. Are prognostic factors more favorable for breast cancer detected by organized screening than by opportunistic screening or clinical diagnosis? A study in Loire-Atlantique (France). Cancer Epidemiol. 2013;37:683–7.CrossRef
14.
go back to reference Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012;380:1778–86.CrossRef Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012;380:1778–86.CrossRef
15.
go back to reference Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012;367:1998–2005.CrossRef Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012;367:1998–2005.CrossRef
16.
go back to reference Pruitt SL, Shim MJ, Mullen PD, Vernon SW, Amick BC 3rd. The association of area socioeconomic status and breast, cervical, and colorectal cancer screening: a systematic review. Cancer Epidemiol Biomark Prev. 2009;18:2579–99.CrossRef Pruitt SL, Shim MJ, Mullen PD, Vernon SW, Amick BC 3rd. The association of area socioeconomic status and breast, cervical, and colorectal cancer screening: a systematic review. Cancer Epidemiol Biomark Prev. 2009;18:2579–99.CrossRef
17.
go back to reference Swan J, Breen N, Coates RJ, Rimer BK, Lee NC. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer. 2003;97:1528–40.CrossRef Swan J, Breen N, Coates RJ, Rimer BK, Lee NC. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer. 2003;97:1528–40.CrossRef
18.
go back to reference Eichholzer M, Richard A, Rohrmann S, et al. Breast cancer screening attendance in two Swiss regions dominated by opportunistic or organized screening. BMC Health Serv Res. 2016;16:519.CrossRef Eichholzer M, Richard A, Rohrmann S, et al. Breast cancer screening attendance in two Swiss regions dominated by opportunistic or organized screening. BMC Health Serv Res. 2016;16:519.CrossRef
19.
go back to reference Chamot E, Charvet AI, Perneger TV. Who gets screened, and where: a comparison of organised and opportunistic mammography screening in Geneva, Switzerland. Eur J Cancer. 2007;43:576–84.CrossRef Chamot E, Charvet AI, Perneger TV. Who gets screened, and where: a comparison of organised and opportunistic mammography screening in Geneva, Switzerland. Eur J Cancer. 2007;43:576–84.CrossRef
20.
go back to reference Sardanelli F, Boetes C, Borisch B, et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer. 2010;46:1296–316.CrossRef Sardanelli F, Boetes C, Borisch B, et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer. 2010;46:1296–316.CrossRef
21.
go back to reference Killelea B, Long J, Chagpar A, et al. Trends and clinical implications of preoperative breast MRI in Medicare beneficiaries with breast cancer. Breast Cancer Res Treat. 2013;141:155–63.CrossRef Killelea B, Long J, Chagpar A, et al. Trends and clinical implications of preoperative breast MRI in Medicare beneficiaries with breast cancer. Breast Cancer Res Treat. 2013;141:155–63.CrossRef
22.
go back to reference Samnakay N, Tinning J, Ives A, et al. Rates for mastectomy are lower in women attending a breast-screening programme. ANZ J Surg. 2005;75:936–9.CrossRef Samnakay N, Tinning J, Ives A, et al. Rates for mastectomy are lower in women attending a breast-screening programme. ANZ J Surg. 2005;75:936–9.CrossRef
Metadata
Title
Comparison between opportunistic and organised breast cancer mammography screening in the Swiss canton of Fribourg
Authors
Sarah Peisl
Stefan Zimmermann
Bertrand Camey
Daniel Betticher
Christine Bouchardy
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5706-1

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine